HyQvia 100 mg/ml solution for infusion for subcutaneous use, HyQvia 100 mg/ml solution for infusion for subcutaneous use, TAK-881
TAK-881-3001
Phase 3 small_molecule active
Quick answer
HyQvia 100 mg/ml solution for infusion for subcutaneous use, HyQvia 100 mg/ml solution for infusion for subcutaneous use, TAK-881 for Primary Immunodeficiency Diseases is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Primary Immunodeficiency Diseases
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active